Provider of EARLY CANCER DETECTION (ECD) TECHNOLOGY www.earlycancerdetect.

com

According to the World Health Organization (WHO) International Agency for Research on Cancer, Lung Cancer is the deadliest type of cancer globally accounting for 1.8 Million people dying each year, or two deaths per minute. In the Philippines, studies showed that 80% of cancer mortality was due to Lung Cancer, having the lowest survival rate at 15%.

Over the last 30 years, doctors have greatly improved the survival rates for many types of cancer. Sadly, Lung Cancer survival rates is the Same and remain one of the top cancer sites. Aggressive but silent, Lung Cancer typically grows without symptoms, not betraying its presence until its too advanced to be cured. 80% of all Lung Cancer patients die within two years after diagnosis, since the tumor is already in its advance stage.
Today, there is hope in improving the chances for survival through early cancer detection, now available in the Philippines.

Risk factors for Lung Cancer

Cigarette smoking is the primary risk factor for lung cancer and 85% of all lung cancer cases are caused by cigarette smoking. An individuals risk for developing Lung Cancer depends on how much theyve smoked, the age at which they started smoking, and the age at which they quit.
For non-smokers, second-hand smoke is the main cause of lung cancer, but other risk factors include : exposure to industrial or environmental carcinogens such as asbestos and radon; and lung disease, especially diseases which scar or damage the lungs. The risk of developing lung cancer also increases with age and heredity.

In the past, if you were worried about having lung cancer, there was no simple test to take. Most patients even high-risk ones were not tested for lung cancer until they showed symptoms of the disease. By then, if lung cancer was present, it was usually too late. Fortunately, times have changed. Pharmacanadas early lung cancer detection test has been designed to check for early-stage lung cancer in high-risk individuals who:
Are over 40 years old Have had significant exposure to: Cigarette smoke (one pack a day for 20 years)
and industrial carcinogens

Have symptoms such as persistent cough or shortness of breath or other indicators like suspicious radiography

The technology for early cancer detection was produced by research at the British Columbia Cancer Agency. It has been established through a multicentered validation trial which demonstrated that fully automated DNA analysis of sputum cells using ClearCyte detects early stage, presymptomatic or stage 1 lung cancer before it is discernable by standard xray or CT scan imaging.

When it comes to lung cancer, early detection is the key in extending the lives and improving the quality of life for those who have the disease. The innovative technology of ClearCyte brings new hope to the battle. It is safe, simple, and a non-invasive test for early detection of lung cancer. By analyzing the lung cells commonly found in sputum, the test can detect cancer before it spreads, increasing the likelihood of successful treatment. Similar to Papsmear Test for cervical cancer or the Prostate Specific Antigen (PSA) test for prostate cancer, the ClearCyte does not provide a yes or no diagnosis but it rather indicates the likelihood that an individual has lung cancer. Although not a diagnostic test, the existence of a likelihood predictor such as ClearCyte is of enormous value in the fight against lung cancer.

The Early Cancer Detection (ECD) test kit provided by Pharmacanada can be used with a number of tools to help obtain the sputum sample necessary for analysis: Lung flute Medication Expectorants Nebulizers Producing a sputum sample using the Pharmacanada kit causes very little physical discomfort. Almost anyone can use the kit, with the following exceptions :

Patients who have had thoracic and cardiac surgery within the last 6 months Patients with asthma or COPD exacerbation in the last 5 days Patients with flu-like symptoms such as fever or chills

ECD test similar to Papsmear test for cervical cancer or the Prostate Specific Antigen (PSA) test for prostate cancer does not provide a yes or no answer to the question : Do I have lung cancer?. Instead, ECD results are presented as a risk multiplier, indicating the statistical likelihood that an individual harbors lungs cancer. ECD test provides an automated analysis of properties of epithelial cells present in sputum specimen. The test measures property of cell nuclei such as DNA content, conformation and texture. It identifies possible malignant cells as well as changes in normal appearing cell nuclei that are associated with the presence of malignancy.

Sputum samples are sent to Pharmacanadas cytology laboratory at St. Dominic Medical Center in Cavite City for analysis. Reports are typically sent to the requesting physician through email within 10 working days of sample receipt by the laboratory, ECD scores should be interpreted in context to an individuals overall health and medical history. Therefore, ECD results are sent to your doctor, who has the expertise necessary to interpret them and recommend any further action. Although not a diagnostic test. People need not wait for signs and symptoms of the disease to manifest before taking the test. The existence of a likelihood predictor such as the ECD provided by Pharmacanada is potentially of enormous value in the fight against lung cancer.

If you would like to take the Early Cancer Detection (ECD) test provided by Pharmacanada, talk with your doctor about your risk of lung cancer, and how ECD is right for you.

If you would like to be tested for lung cancer, contact Pharmacanada at the numbers provided below.
TO ORDER OR FOR MORE INFORMATION : Call : (632) 553-4276, (632) 553-4205 Visit: Pharmacanada Inc. Penthouse 4, VGP Center, 6772 Ayala Ave., Makati City Philippines E-mail: info@pharmacanada.com.ph Website: www.earlycancerdetect.com Test available at select medical and diagnostic centres.

Early Cancer Detection (ECD) test

THANK YOU
Early Cancer Detection Provider